Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 17.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 23.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
| 29.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 31.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
Stammdaten
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Unternehmen & Branche
| Name | Rallybio Corp |
|---|---|
| Ticker | RLYB |
| CIK | 0001739410 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 75120L100 |
|---|---|
| ISIN | US75120L1008 |
| Typ | COM |
| Marktkapitalisierung | 77,5 Mio. USD |
| Beta | -1,10 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 858,000 | -8,978,000 | -1.59 | 62,261,000 | 57,956,000 |
| 2025-09-30 | 10-Q | 212,000 | 16,016,000 | 0.36 | 67,661,000 | 63,034,000 |
| 2025-06-30 | 10-Q | 212,000 | -9,703,000 | -0.22 | 51,003,000 | 45,964,000 |
| 2025-03-31 | 10-Q | 212,000 | -9,439,000 | -0.21 | 57,983,000 | 54,073,000 |
| 2024-12-31 | 10-K | 636,000 | -57,775,000 | -10.61 | 68,108,000 | 61,654,000 |
| 2024-09-30 | 10-Q | 299,000 | -11,466,000 | -0.26 | 79,007,000 | 70,818,000 |
| 2024-06-30 | 10-Q | 299,000 | -16,236,000 | -0.37 | 92,431,000 | 80,017,000 |
| 2024-03-31 | 10-Q | 0 | -19,029,000 | -0.47 | 99,359,000 | 89,157,000 |
| 2023-12-31 | 10-K | -74,564,000 | -1.84 | 115,620,000 | 106,184,000 | |
| 2023-09-30 | 10-Q | 0 | -18,374,000 | -0.45 | 133,194,000 | 123,581,000 |
| 2023-06-30 | 10-Q | 0 | -18,630,000 | -0.46 | 147,576,000 | 139,257,000 |
| 2023-03-31 | 10-Q | -17,318,000 | -0.43 | 162,318,000 | 155,197,000 | |
| 2022-12-31 | 10-K | -66,654,000 | -2.09 | 180,435,000 | 169,317,000 | |
| 2022-09-30 | 10-Q | -18,370,000 | -0.60 | 143,666,000 | 131,943,000 | |
| 2022-06-30 | 10-Q | -17,583,000 | -0.57 | 155,607,000 | 147,851,000 | |
| 2022-03-31 | 10-Q | -14,498,000 | -0.48 | 169,353,000 | 163,036,000 | |
| 2021-12-31 | 10-K | -47,013,000 | -1.84 | 182,185,000 | 175,602,000 | |
| 2021-09-30 | 10-Q | -10,196,000 | -0.37 | 193,865,000 | 186,488,000 | |
| 2021-06-30 | 10-Q | -11,127,000 | -0.49 | 120,097,000 | 112,662,000 | |
| 2021-03-31 | 10-Q | -13,275,000 | 123,250,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 4,194,777 | 0 | 4,194,777 | 2,878,037 | Neu | +100,0% | |
| JOHNSON & JOHNSON | 3,636,363 | 0 | 3,636,363 | 2,494,909 | Neu | +100,0% | |
| 5AM Venture Management, LLC | 3,630,724 | 0 | 3,630,724 | 2,491,040 | Neu | +100,0% | |
| TPG GP A, LLC | 3,028,414 | 0 | 3,028,414 | 2,089,606 | Neu | +100,0% | |
| FMR LLC | 1,694,388 | 0 | 1,694,388 | 1,162,520 | Neu | +100,0% | |
| Almitas Capital LLC | 1,529,653 | 0 | 1,529,653 | 1,049,495 | Neu | +100,0% | |
| AJU IB Investment Co., Ltd. | 94,334 | 754,678 | -660,344 | 846,176 | Reduziert | -87,5% | |
| VANGUARD GROUP INC | 1,016,249 | 0 | 1,016,249 | 697,147 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 835,692 | 0 | 835,692 | 573,368 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 253,842 | 0 | 253,842 | 174,161 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 248,005 | 0 | 248,005 | 170,191 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 11,280 | 0 | 11,280 | 101,182 | Neu | +100,0% | |
| BlackRock, Inc. | 141,663 | 0 | 141,663 | 97,195 | Neu | +100,0% | |
| UBS Group AG | 7,914 | 4,577 | 3,337 | 70,989 | Aufgestockt | +72,9% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 100,724 | 0 | 100,724 | 69,107 | Neu | +100,0% | |
| XTX Topco Ltd | 97,313 | 0 | 97,313 | 66,766 | Neu | +100,0% | |
| STATE STREET CORP | 62,072 | 0 | 62,072 | 42,588 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 38,124 | 0 | 38,124 | 26,157 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 37,000 | 0 | 37,000 | 25,386 | Neu | +100,0% | |
| PRUDENTIAL FINANCIAL INC | 29,100 | 0 | 29,100 | 19,966 | Neu | +100,0% | |
| OneDigital Investment Advisors LLC | 20,000 | 0 | 20,000 | 13,722 | Neu | +100,0% | |
| Ground Swell Capital, LLC | 15,399 | 0 | 15,399 | 10,565 | Neu | +100,0% | |
| GREAT VALLEY ADVISOR GROUP, INC. | 15,000 | 0 | 15,000 | 10,292 | Neu | +100,0% | |
| Utah Retirement Systems | 13,240 | 0 | 13,240 | 9,084 | Neu | +100,0% | |
| ACT Advisors, LLC. | 13,153 | 0 | 13,153 | 9,024 | Neu | +100,0% | |
| MERCER GLOBAL ADVISORS INC /ADV | 10,000 | 0 | 10,000 | 6,861 | Neu | +100,0% | |
| Hartford Financial Management Inc. | 6,500 | 0 | 6,500 | 4,460 | Neu | +100,0% | |
| BARCLAYS PLC | 5,719 | 0 | 5,719 | 3,924 | Neu | +100,0% | |
| MORGAN STANLEY | 4,640 | 0 | 4,640 | 3,183 | Neu | +100,0% | |
| Tower Research Capital LLC (TRC) | 4,524 | 0 | 4,524 | 3,104 | Neu | +100,0% | |
| SBI Securities Co., Ltd. | 4,248 | 0 | 4,248 | 2,915 | Neu | +100,0% | |
| CITIGROUP INC | 3,932 | 0 | 3,932 | 2,698 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 980 | 0 | 980 | 672 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 300 | 0 | 300 | 206 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 251 | 0 | 251 | 172 | Neu | +100,0% | |
| ACADIAN ASSET MANAGEMENT LLC | 83,480 | 0 | 83,480 | 56 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 82 | 0 | 82 | 56 | Neu | +100,0% | |
| Allworth Financial LP | 50 | 0 | 50 | 35 | Neu | +100,0% | |
| Virtu Financial LLC | 27,132 | 0 | 27,132 | 19 | Neu | +100,0% | |
| HRT FINANCIAL LP | 21,387 | 0 | 21,387 | 14 | Neu | +100,0% | |
| GSA CAPITAL PARTNERS LLP | 19,303 | 0 | 19,303 | 13 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Purchase | 35,101 | 14.00 | 491,259.56 | +67,6% | |
| 2026-05-04 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Purchase | 3,900 | 13.90 | 54,201.42 | +7,5% | |
| 2026-05-04 | ADAR1 Capital Management, LLC | 10% Owner | Open Market Purchase | 116,904 | 13.97 | 1,633,207.33 | +224,9% |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| AJU IB Investment Co., Ltd. | 94,334 | 846,176 | 83.09 |
| DIMENSIONAL FUND ADVISORS LP | 11,280 | 101,182 | 9.94 |
| UBS Group AG | 7,914 | 70,989 | 6.97 |